Please assess the completion status of the following clinical trial:

Trial Title: Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Histological proven cancer of the breast.~* Progressive and/or metastatic disease.~* No further standard treatment for the patient available or the patient does not wish to receive the offered standard treatment.~* If Endocrine therapy: Progression in cutaneous lesions.~* If treatment with trastuzumab (Herceptin)can continue this treatment if there is no regression in cutaneous lesions.~* At least 2 weeks since last chemotherapy, patients treated with Navelbine (Vinorelbine), Capecitabin (Xeloda) or weekly Paclitaxel (Taxol)can continue this treatment if there is no regression in cutaneous metastases.~* Malignant cutaneous or subcutaneous lesion to be treated ≥ 3 cm.~* WHO performance ≤ 2.~* Life expectancy of at least 3 months.~* Platelets ≥ 50 mia/l, pp ≥ 40, APTT in normal area. Medical correction is allowed.~* Sexual active men and women must use safe anticonceptive during and up to 6 month after last treatment.~* Written informed consent must be obtained according to the local Ethics committee requirements.~Exclusion Criteria:~* Acute lung infection~* Previous bleomycin treatment exceeding 200.000 Units/m2.~* Known hypersensitivity to any of the components of the treatment.~* Known hypersensitivity to any of the components used in the planned anesthesia.~* Pregnant or lactating women. In fertile women this is ensured by measuring HCG in blood.~* Treatment with granulocyte colony stimulating factor (G-CSF) or other cytokines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Patients with local-regional recurrence of breast cancer, lesion over 3 cm.

Based on this trial design, predict the completion outcome and termination type (if applicable).